Clinical Trial Update: Tyrosine Kinase Inhibitor (TKI) + Anti-PD-1 Antibody in TKI-responded Microsatellite Stability/Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Adenocarcinoma. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a tyrosine kinase inhibitor plus anti-PD-1 antibody in MSS/pMMR metastatic colorectal adenocarcinoma after TKI response; current status…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Adenocarcinoma
• Mss
• Pmmr

Drugs mentioned

• Anti-PD-1 antibody
• Tyrosine kinase inhibitor (TKI)

Snippet

Sponsor: China Medical University, China | Conditions: MSS, pMMR | Phase 2 | Status: UNKNOWN